Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia
Denis Y. Logunov, Inna V. Dolzhikova, Mamadou Y. Boiro, Anna V. Kovyrshina, Alina S. Dzharullaeva, Alina S. Erokhova, Daria M. Grousova, Amir I. Tukhvatulin, Fatima M. Izhaeva, Yana V. Simakova, Maria K. Ordzhonikidze, Nadezhda L. Lubenets, Olga V. Zubkova
TL;DR
A new Ebola vaccine called GamEvac-Combi was tested in a clinical trial and found to be safe and effective at triggering strong immune responses.
Contribution
The study presents a novel heterologous rVSV- and rAd5-vectored Ebola vaccine and evaluates its safety and immunogenicity in a multicenter trial.
Findings
The vaccine induced strong cell-mediated and humoral immune responses, with high seroconversion rates.
Neutralizing antibody levels remained elevated for at least one year after vaccination.
The vaccine demonstrated a favorable safety profile over the 12-month observation period.
Abstract
Ebola virus disease (EVD) is one of the most dangerous and lethal diseases affecting humans. There are several licensed vaccines against EVD, but it remains one of the priority diseases for research and development of effective vaccines. A double-blind randomized placebo-controlled trial was performed to evaluate safety and immunogenicity of rVSV- and rAd5-vectored vaccine GamEvac-Combi in healthy adults of both sexes between 18 and 60 years. Safety and immunogenicity were assessed during the observation period of 12 months. Immunogenicity was assessed with GP-specific ELISA, IFN-γ ELISA, and plaque pseudoneutralization assay. Vaccinated participants showed marked GP-specific IFN-γ response at day 28 and neutralizing response at day 42 (GMT = 32.6, seroconversion rate 96.3%). GP-specific IgG antibody levels in vaccinated participants peaked at day 42 (GMT = 9345) and persisted for a…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsViral Infections and Outbreaks Research · Hepatitis B Virus Studies · Viral Infections and Vectors